|
|
||
|
|
Pittsburgh, PA - February 7, 2005 - The U.S.
Patent and Trade Office has awarded Automated Cell patent #6,830,931 for an
apparatus and method for analyzing the effect of proteins and other
biological and chemical moieties on living cells. Claims include: the
measurement of the 3D motion of cells; capturing successive fluorescent and
visible images over time and analyzing the successive images to produce time
related kinetic information; and the statistical analysis of that information
to measure cellular performance. The patent refers to Automated Cell’s
functional biology imaging platform, CytoWorks™, which it employs to screen
its human antibody libraries for therapeutic drug leads in the field of
cancer. Raymond K. Houck, Automated Cell’s CEO, stated “This patent provides
us with further intellectual property that applies to our functional biology
approach to the identification of antibody therapeutics. The US Patent office
has issued one set of claims and we are proceeding with the prosecution of
the many additional claims of the original application”. About Automated Cell Automated Cell Inc, (ACI) is focused on the discovery and development of monoclonal antibody therapeutics for the treatment of cancer. Our unique and proprietary technology allows us to rapidly identify fully human antibodies that have relevant biological function in a specific disease. Our starting point for drug discovery is the identification of these functional antibodies. We then use the antibodies to identify and validate their targets, shortening the path to the clinic. We are creating a pipeline of antibody therapeutic candidates that we shall either out-license to pharmaceutical partners or put into clinical trials ourselves. For more information, please contact: Kevin Sullivan, VP
Business Development at 412-826-5203 or ksullivan@automatedcell.com. Copyright © 2005, Automated Cell, Inc. |
|
